Skip to content

Single centre randomised study to discover whether fibrin glue is more effective than surgery in the treatment of pilonidal sinus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN56652573
Enrollment
40
Registered
2006-09-29
Start date
2005-03-30
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases: Pilonidal sinus Skin and Connective Tissue Diseases Pilonidal sinus

Interventions

Randomised Controlled Trial. Patients that present with pilondial sinus at outpatient clinic will be invited to participate in the study. Forty patients will be recruited. Having given informed consen

Sponsors

Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with pilonidal sinus under the care of Consultant Surgeons within the Derby NHS Foundation Trust will be identified from GP referral letters to surgical outpatients. Patients will be approached on visiting outpatients. Patients will be given both verbal and written information to enable them to make an informed decision as to whether to proceed. Patients have the right to withdraw at any stage. Inclusion criteria: 1. Male and Female subjects with pilonidal sinus 2. Patients > 18 years old 3. Only women taking adequate contraceptive precautions 4. Patients with no history of allergy to any of the product contents of Tisseel Kit sealant. 5. Ability to provide valid informed consent. 6. Patients who have no objections on moral/religious grounds to the product (Tisseel contains human fibrin and Aprotinin from cattle)

Exclusion criteria

Exclusion criteria: 1. Women who are lactating 2. Women who are pregnant 3. Women of childbearing age who are unwilling to take adequate contraceptive precautions 4. Patients with allergic diathesis or patients who have had previous exposure to aprotinin

Design outcomes

Primary

MeasureTime frame
1. Reduction in Pain 2. Healing rate.

Secondary

MeasureTime frame
Added September 2008: Recurrence, infection, return to work and cost.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026